Evidence map›Paper›PMID 27421070›Full record

ReviewCurrent opinion in microbiology2016

Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes.

Michael R Hamblin

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 2 pooled it
47.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

231 citing papers in PubMed, 2 syntheses or guidelines pooled it, 731 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Zerumbone combined with antimicrobial photodynamic inactivation reduces growth of Candida albicans biofilms and modulates virulence gene expression.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  8. Article
  9. Review
  10. Light-driven bacterial inactivation using Plumeria rubra extract: a promising natural photosensitizer.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

171 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. Electronic address: hamblin@helix.mgh.harvard.edu.
Harvard University · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

Photodynamic therapy (PDT) uses photosensitizers (non-toxic dyes) that are activated by absorption of visible light to form reactive oxygen species (including singlet oxygen) that can oxidize biomolecules and destroy cells. Antimicrobial photodynamic inactivation (aPDI) can treat localized infections. aPDI neither causes any resistance to develop in microbes, nor is affected by existing drug resistance status. We discuss some recent developments in aPDI. New photosensitizers including polycationic conjugates, stable synthetic bacteriochlorins and functionalized fullerenes are described. The microbial killing by aPDI can be synergistically potentiated (several logs) by harmless inorganic salts via photochemistry. Genetically engineered bioluminescent microbial cells allow PDT to treat infections in animal models. Photoantimicrobials have a promising future in the face of the unrelenting increase in antibiotic resistance.

Indexed as

Bacterial InfectionsBromidesFullerenesIodidesLightMycosesParasitic DiseasesPhotochemotherapyPhotosensitizing AgentsPorphyrinsReactive Oxygen SpeciesSodium AzideVirus DiseasesbacteriochlorinBromidesFullerenesIodidesPhotosensitizing AgentsPorphyrinsReactive Oxygen SpeciesSodium Azide

Identifiers

PMID27421070
PMCPMC5069151
OpenAlexW2475022942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.